The Cupertino, CA-based company released preliminary data from the Apple Heart Study, which demonstrates the effectiveness of wearables to detect atrial fibrillation.
R-One is the first European robotic solution to obtain the CE mark in the field of interventional cardiology.
The Abbott Park, IL-based company’s expanded indication would allow the MitraClip to address the secondary form of mitral regurgitation and would significantly increase the amount of people with MR able to be treated by the device.
Watchman has been a significant driver for Boston Scientific and is expected to have strong growth this year as well.
A medtech analyst says recent developments have created more uncertainty about paclitaxel-coated balloons and stents.
As the Irvine, CA-based company strengthens its mitral valve portfolio, it also faces a lawsuit from Abbott Laboratories over the Pascal system.
Ablative Solutions revealed data from the Peregrine Post-Market Study during the 2019 Cardiovascular Research Technologies meeting in Washington D.C. recently.
The Dublin-based company received approval for an expanded chronic total occlusion indication for its Resolute DES platform.
The Lake Oswego, OR-based company has received a nod from FDA for the Orsiro stent which it said outperformed Abbott’s Xience stent in a clinical study.
The Salt Lake City-based company said its Tria device is one of the first biopolymer heart valve platforms.
Duke University Medical Center researchers looked at data from 9,000 patients who underwent Cardiac Magnetic Resonance.
The Fully Implanted Ventricular Assist Device was developed using technologies from Jarvik Heart and Leviticus Cardio.
Edwards might be primarily known for its TAVR systems, but the company has been making some interesting forays into the artificial intelligence realm.